Effect of daptomycin on local interleukin-6, matrix metalloproteinase-9, and metallopeptidase inhibitor 1 in patients with MRSA-infected diabetic foot

International Journal of Lower Extremity Wounds

Volumn 12, Issue 2, 2013, Pages 100-105

  Ambrosch, Andreas ^a,b   Halevy, Daniel ^c   Fwity, Boushra ^b   Brin, Thomas ^b   Lobmann, Ralf ^c  

^a Institute of Medical Microbiology and Hygiene   (Germany)

^b Institute of Laboratory Medicine and Microbiology   (Germany)

^c Medical Clinic 3   (Germany)

Author keywords

daptomycin; diabetic foot; MMP 9; MRSA; TIMP 1

Indexed keywords

DAPTOMYCIN; GELATINASE B; INTERLEUKIN 6; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); DIABETIC FOOT; DIABETIC PATIENT; DISEASE CLASSIFICATION; DRUG EFFECT; FEMALE; HUMAN; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; PRIORITY JOURNAL; WOUND FLUID; WOUND HEALING;

DAPTOMYCIN; DIABETIC FOOT; MMP-9; MRSA; TIMP-1;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DIABETIC FOOT; FEMALE; HUMANS; INTERLEUKIN-6; LONGITUDINAL STUDIES; MALE; MATRIX METALLOPROTEINASE 9; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; PILOT PROJECTS; STAPHYLOCOCCAL INFECTIONS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; WOUND HEALING;

EID: 84879375515     PISSN: 15347346     EISSN: 15526941     Source Type: Journal    
DOI: 10.1177/1534734613490506     Document Type: Article

References (30)

1. Lipsky BA, Tabak YP, Johannes RS, Vo L, Hyde L, Weigelt JA. Skin and soft tissue infections in hospitalized patients with diabetes: culture isolates and risk factors associated with mortality, length of stay and cost. Diabetologia. 2010 ; 53: 914-923
2. Richard JL, Sotto A, Jourdan N, et al. Risk factors and healing impact of multidrug resistant bacteria in diabetic foot ulcers. Diabetes Metab. 2008 ; 34: 363-369
3. Ramakant P, Verma AK, Misra R, et al. Changing microbiological profile of pathogenic bacteria in diabetic foot infections: time for a rethink on which empirical therapy to choose. Diabetologia. 2011 ; 54: 58-64
4. Sader HS, Fey FD, Limaye AP, et al. Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. Antimicrob Agents Chemother. 2009 ; 53: 4127-4132
5. Stein GE, Schooley S, Peloquin CA, Missavage A, Havlichek DH. Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections. J Antimicrob Chemother. 2007 ; 60: 819-823
6. Lipsky BA, Itani K, Norden C. Linezolid diabetic foot infections study group. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin/amoxicillin-clavulanate. Clin Infect Dis. 2004 ; 38: 17-24
7. French GL. Bactericidal agents in the treatment of MRSA infections - the potential role of daptomycin. J Antimicrob Chemother. 2006 ; 58: 1107-1117
8. Lobmann R, Schultz G, Lehnert H. Proteases and diabetic foot syndrome: mechanisms and therapeutic implications. Diabetes Care. 2006 ; 28: 461-471
9. Lavery LA, Armstrong DG, Harkless LB. Classification of diabetic wounds. J Foot Ankle Surg. 1996 ; 35: 528-531
10. German Diabetes Association. The official standardized wound information sheet from the Diabetic Foot Working Group of the German Diabetes Association. http://www.ag-fuss-ddg.de. Published 2006. Accessed May 21, 2013.
11. Barro C, Romaner JP, Fdili A, Guillot M, Morel F. Gelatinase concentration in tears of corneal-grafted patients. Curr Eye Res. 1998 ; 17: 174-182
12. Vardakas KZ, Horianopoulou M, Falagas ME. Factors associated with treatment failure in patients with diabetic foot infections: an analysis of data from randomized controlled trials. Diabetes Res Clin Pract. 2008 ; 80: 344-351
13. Tentolouris N, Jude EB, Smirnof I, Knowles EA, Boulton AJ. Methicillin-resistant Staphylococcus aureus: an increasing problem in a diabetic foot clinic. Diabet Med. 1999 ; 16: 767-771
14. Richard JL, Sotto A, Jourdan N, et al. Risk factors and healing impact of multidrug resistant bacteria in diabetic foot ulcers. Diabetes Metab. 2008 ; 34: 363-369
15. Trengove NJ, Bielefeldt-Ohmann H, Stacey MC. Mitogenic activity and cytokine levels in non-healing and healing chronic leg ulcers. Wound Repair Regen. 2000 ; 8: 13-25
16. Wallace HJ, Stacey MC. Levels of tumor necrosis factor alpha (TNF-α) and soluble TNF receptors in chronic venous leg ulcers - correlations to healing status. J Invest Dermatol. 1998 ; 110: 292-296
17. Chen SM, Ward SI, Olutoye OO, Diegelmann RF, Kelman I. Ability of chronic wound fluids to degrade peptide growth factors is associated with increased levels of elastases activity and diminished levels of proteinase inhibitors. Wound Repair Regen. 1997 ; 5: 23-32
18. Schmohl M, Beckert S, Joos T, Konigsrainer A, Schneiderhahn-Marra N, Löffler M. Superficial wound swabbing: a novel method of sampling and processing wound fluid for subsequent immunoassay analysis in diabetic foot ulceration. Diabetes Care. 2012 ; 35: 2113-2120
19. Fluit AC, Schmitzu FJ, Verhoef J, Milatovic D. In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistant determinants. Antimicrob Agents Chemother. 2004 ; 48: 1007-1011
20. Streit JM, Jones RN, Sader HS. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical gram-positive organisms. J Antimicrob Chemother. 2004 ; 53: 669-674
21. Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother. 2005 ; 55: 240-245
22. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004 ; 38: 1673-1681
23. Ambrosch A, Lobmann R, Pott A, Preissler J. IL-6 concentrations rather than serological markers are useful in assessing bacterial triggers of ulcer inflammation. Int Wound J. 2008 ; 5: 99-106
24. Dinh T, Tecilazich F, Kafanas A, et al. Mechanisms involved in the development and healing of diabetic foot ulceration. Diabetes. 2012 ; 61: 2937-2947
25. Lobmann R, Zemlin C, Motzkau M, Reschke K, Lehnert H. Expression of matrix metalloproteinases and growth factors in diabetic foot wounds treated with protease absorbent dressing. J Diabetes Complications. 2006 ; 20: 329-335
26. Lobmann R, Ambrosch A, Schultz G, Waldmann K, Schieweck S, Lehnert H. Expression of matrix-metalloproteinases and their inhibitors in the wounds of diabetic and non-diabetic patients. Diabetologia. 2002 ; 45: 26-37
27. Vaalamo M, Weckroth M, Puolakkainen P, et al. Patterns of matrix metalloproteinases and TIMP-1 expression in chronic and normally healing human cutaneous wounds. Br J Dermatol. 1996 ; 135: 52-59
28. Liu Y, Min D, Bolton T, et al. Increased matrix metalloproteinase-9 predicts poor wound healing in diabetic foot ulcers. Diabetes Care. 2009 ; 32: 117-119
29. Falanga V. Wound healing and its impairment in the diabetic foot. Lancet. 2005 ; 366: 1736-1743
30. Kessler L, Piemont Y, Ortega F, et al. Comparison of microbiological results of needle puncture vs. superficial swab in infected diabetic foot ulcer with osteomyelitis. Diabet Med. 2006 ; 23: 99-102